KoreaMed Synapse


1	Comparison Between Paclitaxel-Carboplatin and Paclitaxel-Cisplatin as a Combination Chemotherapy in Recurrent Ovarian Cancer Hang Jo Yoo, Yong Man Kim, Hea Rim Lee, Mi Kyung Kim, Dong Heon Lee, Jong Hyeok Kim, Young Tak Kim, Jung Eun Mok, Joo Hyun Nam Korean J Gynecol Oncol Colposc.2001;12(2):120-127. Published online 2019 March 13 DOI: http://dx.doi.org/10.3802/kjgoc.2001.12.2.120

2	The Response Rate of Carboplatin/Paclitaxel for the Platinum Sensitive Recurrent Ovarian Cancer Patients Hye Jin Chang, Hee Sug Ryu, Yun Kyoung Lim, Se Hee Moon, Ki Hong Chang, Jung Pil Lee Korean J Gynecol Oncol Colposc.2003;14(4):275-280. Published online 2019 March 12 DOI: http://dx.doi.org/10.3802/kjgoc.2003.14.4.275

3	Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Tomokazu Umezu, Shiro Suzuki, Ryuichiro Sekiya, Kaoru Niimi, Hiroko Mitsui, Eiko Yamamoto, Michiyasu Kawai, Tetsuro Nagasaka, Fumitaka Kikkawa J Gynecol Oncol.2014;25(1):43-50. Published online 2014 January 8 DOI: http://dx.doi.org/10.3802/jgo.2014.25.1.43

4	Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer Jaeman Bae, Myong Cheol Lim, Jae-Ho Choi, Yong-Joong Song, Kyoung-Soo Lee, Sokbom Kang, Sang-Soo Seo, Sang-Yoon Park J Gynecol Oncol.2009;20(2):101-106. Published online 2009 June 29 DOI: http://dx.doi.org/10.3802/jgo.2009.20.2.101